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7 Abstract
8 The aim of this study was to study the clinical effectiveness of a structured home modeling (HM) protocol in Peyronie’s
9 disease (PD) patients who have residual curvature up to 45° after inflatable penile prosthesis (PP) placement. A total of 92
10 patients with PD and coexistent refractory erectile dysfunction received inflatable PP. If residual curvature after manual
11 modeling (MM) was more than 45°, incision–grafting was performed. If curvature was <45° after MM, patients were
12 instructed to perform HM daily for 6 months, after 4 weeks from PP implantation. The mean preoperative penile curvature
13 was 39.4 ± 5.7° (30–60). Sixteen (17.4%) patients required incision–grafting and the remaining 76(82.6%) patients followed
14 HM protocol. The mean postoperative residual curvature after MM was 29.7 ± 3.2° (5–50). Sixty-five (85.5%) patients who
15 underwent HM had 10° or less residual curvature after 3 months and 72 (94.7%) patients had 10° or less residual curvature
16 after 6 months. Seventy (92.1%) patients responded as satisfied or very satisfied on the questionnaire with the outcome after
17 6 months. HM of the penis over Inflatable PP may straighten the penis without the need for an additional surgical maneuver
18 in vast majority of the PD patients having residual curvature of <45°.
19 Introduction
20 Peyronie’s disease (PD) is a connective tissue disorder
21 which mainly affects the tunica albuginea of the penis,
22 which may lead to penile curvature and/or erectile dys-
23 function (ED) [1]. The etiopathogenesis of PD is still less
24 understood and lot more research is still needed in under-
25 standing the disease [2].Q1Q2345
26 Acute phase of PD primarily involves conservative
27 management, although few studies report success with
28 collagenase clostridium histolyticum (CCH) injection [3]
29and/or penile traction therapy (PTT) [4] in acute phase, but
30the evidence is weak on the same. Chronic phase of PD is
31the right opportunity for surgical intervention when the
32penile curvature stabilizes [5]. Q6
33Penile prosthesis (PP) becomes the mainstay of man-
34agement in patients with PD with coexistent ED [6]. Resi-
35dual curvature poses a significant Q7hurdle after PP
36implantation [7]. In spite of Wilson’s intraoperative manual
37modeling (MM) [8] over a PP, significant penile curvature
38may persist when the preoperative curvature is beyond 60°
39[9]. Additional surgical interventions like grafting may add
40to the peri-operative morbidity including increased infection
41rates and higher costs [10, 11]. Nevertheless, in many ser-
42ies, as many as up to 40% of patients need surgical cor-
43rection of the curvature in addition to PP [12].
44After intralesional CCH injection, home modeling (HM)
45forms an integral aspect of penile rehabilitation program to
46improve the results [13]. Applying a similar concept [13],
47Moncada’s HM protocol after inflatable penile prosthesis
48(IPP) implantation helps improve penile curvature thereby
49reducing the additional surgical maneuvers.
50The primary aim of the study was to assess the residual
51penile curvature postoperatively after 6 months of HM.
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52 Materials and methods
53 A retrospective review of prospectively collected data was
54 performed of all patients diagnosed with PD who underwent
55 IPP implantation between 2008 and 2017. Institutional
56 review board approval was obtained. All patients received
57 AMS 700-CX IPP (Boston Scientific Corp, Marlborough,
58 MA, USA) through a standard peno-scrotal approach. After
59 implantation, the IPP was inflated to maximum and penile
60 curvature was measured using goniometer. All patients
61 underwent subsequent Wilson’s MM [8] in the
62 operating room.
63 If the residual curvature was more than 45°, circumcision
64 and incision–grafting were performed. Rest of the patients
65 with <45° residual curvature after MM were instructed to
66 perform HM after 4 weeks from implantation.
67 The HM protocol consisted of (1) full inflation of the IPP
68 and gently bending (modeling) the penis in the opposite
69 direction of the curvature, (2) each cycle consisted of
70 holding the penis in this stretched position for 30 s, and then
71 subsequently deflating the IPP, (3) such multiple cycles
72 were done in each episode lasting for 20 min, and (4) such
73 three episodes were done every day for 6 months. The HM
74 was first instructed in office by the urologist after 4 weeks
75 of surgery and subsequently done by the patient himself
76 at home.
77 Demographic and surgical data were collected from the
78 patient medical records. Improvement in penile curvature
79 and patient satisfaction was assessed postoperatively using a
80 non-validated questionnaire (Supplementary Fig. 1). The
81 main outcome measure was the residual curvature at
82 6 months postoperatively.
83 Results
84 The mean age of the study group was 62.8 ± 2.7 years
85 (52–79) (Table 1). A total of 92 patients with PD and
86 coexistent ED received IPP. The mean preoperative penile
87 curvature was 39.4 ± 5.7° (30–60). Sixteen (17.4%) patients
88 required incision–grafting and the remaining 76 (82.6%)
89 patients followed HM protocol. The mean postoperative
90 residual curvature after MM was 29.7 ± 3.2° (5–50). Sixty-
91 five (85.5%) patients who underwent HM had 10° or less
92 residual curvature after 3 months and 72 (94.7%) patients
93 had 10° or less residual curvature after 6 months (Table 2).
94 Seventy (92.1%) patients responded as satisfied or very
95 satisfied on the questionnaire with the outcome after
96 6 months. The following complications were noted after
97 IPP: hematoma not requiring surgery (six patients), pain
98 lasting <6 weeks (four), pump revision for malfunction
99 (one), mechanical failure—tubing leakage (one), and
100impending erosion (one). No revision surgery was needed
101in the first 3 months postoperatively.
102Discussion
103The two important goals of surgery in PD are restoration of
104erectile function and penile curvature correction for a
105satisfactory sexual intercourse [14]. PP becomes the main-
106stay of management in patients with PD with coexistent ED
107[6]. Simultaneously, procedures like plication or
108incision–grafting are usually done if residual curvature
109persists beyond 30°even after MM [5].
110The additional surgical maneuvers needed after IPP
111implantation in PD ranges between 19 and 42% and may be
112associated with complications [7, 12, 15–17]. Terrier et al.
113pointed out that the penile sensory changes range from 2 to
11421% after incision–grafting and it may take up to 1 year for
115the resolution of complete loss of sensation [18]. Graft
116herniation, penile sensory changes, glans edema, recurrence
117of curvature due to graft contraction, and graft infection
118rates vary significantly depending on the type of graft used
119[15–17].
120American Urological Association guidelines on PD
121recommend the use of only IPP and not malleable PP in PD;
122however, this is only an “Expert Opinion” [19]. Our study
123included the use of IPP only. Although MM can be done
124over a malleable PP, IPP is still the most preferred option
125for MM. Garaffa et al. reported that a three-piece IPP pro-
126vides better strength than the malleable for MM. In his
127study group of 209 patients, adequate straightening was
Table 1 Patient's characteristics.




Age (years) 62.8 ± 2.7
Table 2 Results.
Penile curvature Preoperative After manual
modeling
39.4 ± 5.7° (30–60) 29.7 ± 3.2°
(5–50)
Number of patients Incision–grafting Home modeling
16 (17.4%) 76 (82.6%)
Number of patients with
residual penile curvature
<10°
At 3 months At 6 months
65 (85.5%) 72 (94.7%)










128 achieved in 89.6% of cases with a three-piece IPP and
129 53.8% with a malleable PP [12].
130 There are few studies [20–22] highlighting the role of
131 IPP acting as a tissue expander by stretching the corpora
132 over few months and all these studies have different post-
133 operative IPP cycling protocols stating improvements in
134 penile length. None of these studies [20–22] commented on
135 improvements in penile curvature with cycling of IPP,
136 probably due to the correction of curvature by additional
137 surgical maneuvers.
138 Wilson et al. [20] proposed a protocol which achieved
139 girth and length enhancement by 2–4 cm in patients with
140 previous infection, but only girth enhancement in patients
141 with prior priapism. The protocol involved inflating the
142 IPP for up to 3 h daily over a period of 8–12 months. In 40
143 patients, Henry et al. [21] followed a protocol which
144 involved daily inflation of the IPP from 6 weeks to 1 year
145 with a compulsory inflation of 1–2 h in last 6 months.
146 With this, they noted improvements in penile length,
147 penile circumference, girth and satisfaction rates at
148 12 months. Penile length increased by 1.14, 0.99, and
149 1.04 cm for erect, flaccid, and stretched penis, respec-
150 tively, at 12 months. Chung et al. [22] accessed the
151 American Medical Systems and Coloplast Patient Infor-
152 mation Form databases of 2749 patients and reported that
153 60% of patients increased >0.5 cm and 40% increased
154 ≥1 cm in IPP cylinder length at ≥2 years. The authors
155 highlighted the possible role of IPP as a tissue expander to
156 increase internal penile length.
157 PTT has gained popularity in recent years, it being a
158 nonsurgical modality to treat PD. The clinical studies
159 reporting the efficacy of PTT have small study groups and
160 lack randomization and patient compliance [23, 24].Q8 The
161 European Association of Urology 2019 guidelines confer a
162 “weak” recommendation for the use of PTT to reduce penile
163 deformity and increase the penile length [25]. Mechan-
164 otransduction is a process that converts mechanical stimuli
165 to cellular biochemical responses.
166 With the use of mechanical traction and tissue expansion
167 therapy, alteration of connective tissue by cellular pro-
168 liferation and expansion of the extracellular matrix have
169 been demonstrated [26]. Having borrowed the concept of
170 mechanotransduction from bone remodeling [27] and
171 Dupuytren’s contracture studies [28], Chung et al. [29]
172 performed the first in vitro experimental analysis to study
173 the efficacy of tissue traction therapy in PD. Chung et al.
174 documented significant alterations in the ultrastructure of
175 connective tissue with increased collagenase activity and
176 decreased collagen–elastin staining. We assume that IPP
177 does the role of PTT as the postoperative IPP cycling causes
178 repeated stretching of tunica albuginea which results in
179 mild-moderate correction of penile curvature, thereby
180 avoiding additional surgical maneuvers. The strong build
181quality of the IPP cylinders can withstand the pressures
182during HM and MM. The cylinder tubings are clamped
183during intraoperative MM, which of course is not done
184during HM.
185The IMPRESS trial [13] mentioned about the penile
186plaque modeling done by the physician during the first visit
187after two CCH injections and subsequent HM was done by
188the patient himself. Ziegelmann et al. [30] slightly modified
189this protocol and instructed his patients to perform the HM
190themselves (rather than the physician) beginning on the first
191day of the CCH injection [21]. Like in IMPRESS trial [13],
192in our study, the first modeling session was done by the
193physician in the clinic when the patient came for the first
194postoperative visit at 4 weeks and subsequent ones were
195done by the patient himself at home. We noted that no cases
196of tunical rupture due to HM, and it was well accepted by
197majority of patients.
198HM after IPP has not been documented in the literature
199for residual curvature correction, although studies [20–22]
200have reported on penile length and girth increment after
201IPP. This would be the first study to highlight the impor-
202tance of HM after IPP for residual curvature correction even
203up to 45°. Limitations of this study include: (a) use of a non-
204validated questionnaire to assess satisfaction, (b) recall bias
205as 6 months is a longer time for recall period in a
206questionnaire-based assessment, (c) lack of power analysis,
207and (d) lack of a control group.
208Conclusion
209This is a pilot study reporting the effectiveness of HM and
210is a viable option in preventing adjunctive surgical man-
211euvers after IPP implantation even up to residual curvature
212of 45°. The HM protocol described in our study is patient
213friendly, easily reproducible, and not cumbersome. Six
214months of HM gives satisfactory results with no adverse
215effects.
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